Biocytogen is committed to developing innovative antibody drugs that meet the needs of patients, focusing on oncology, autoimmune, inflammatory, metabolic and and other diseases. Taking full advantage of its unique advantage in innovative drug development, the company now has more than 10 R & D pipelines including monoclonal antibodies, bispecific antibodies, ADC drugs and so on. Our pipeline is supported by a strong clinical development team and abundant clinical resources.
To learn more about our pipeline, please contact [email protected].
Candidate |
Target |
Combination |
Indication |
Phase |
Upcoming Milestone |
Rights |
News/Press Release |
|
Clinical-stage Drug Candidates |
YH003 |
CD40 |
PD-1 | Melanoma | Global MRCT
Phase II |
2022 Q4 Complete Recruitment | Global | Biocytogen/Eucure Biopharma Announce First Patient Dosed in Phase II Clinical Trial of YH003 Combination Therapy as a First-Line Treatment for Mucosal Melanoma |
| PD-1 | Pancreatic cancer |
Global MRCT
Phase II |
2022 Q4 Complete Recruitment | |||||
| Monotherapy |
Solid tumors | China Phase I | 2022 Q2 Patient Recruitment |
|||||
| PD-1+ YH001 |
Solid tumors | Australia
IND |
2023 Q1 Complete Recruitment | |||||
| PD-1 | Mucosal melanoma | China | 2022 Q3 Complete Recruitment | |||||
| YH001 |
CTLA-4 |
PD-1 | Non-small-cell lung cancer (NSCLC) |
Global MRCT
Phase II |
2023 Q1 Patient Recruitment |
Global |
Biocytogen/Eucure Biopharma to Present Clinical Data from YH003 (anti-CD40 mAb) and YH001 (anti-CTLA-4 mAb) Trials at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting |
|
| PD-1 | Hepatocellular carcinoma (HCC) |
Global MRCT
Phase II
|
2023 Q1 Patient Recruitment |
|||||
| Monotherapy | Solid tumors | China
Phase I |
2022 Q2 Complete Site Visit | |||||
| PD-L1 | Sarcoma | Global MRCT | 2022 Q3 Patient Recruitment |
|||||
| YH002 |
OX40 |
Monotherapy | Solid Tumors | Australia
Phase 1 |
2022 Q3 Complete Phase I trial |
Global | First Patient Dosing for a Phase I Multi-regional Clinical Trial of YH002 (Anti-OX40 mAb) in Combination with YH001 (Anti-CTLA-4 mAb) in Australia | |
| Monotherapy | Solid Tumors | China/USA
Phase 1 |
Launch based on clinical results in Australia |
|||||
| YH001 | Solid Tumors | China/Australia
Phase I |
2023 Q1 Complete Recruitment | |||||
| YH004 |
4-1BB |
PD-1 | Hematological malignancies |
Australia
Phase 1 |
2023 Q4 Complete Recruitment | Global | ||
| PD-1 | Solid tumors | Australia/China
Phase 1
|
2023 Q4 Complete Recruitment | |||||
| YH005-ADC | Claudin18.2- ADC |
Solid tumors | Australia
IND -> Phase 1 |
Remegen | ||||
| Developmental -stage Drug Candidates |
YH008 | PD-1/CD40 (bispecific antibody) |
Solid tumors | CMC | Global | |||
| YH006 | CTLA-4/ OX40 (bispecific antibody) |
Solid Tumors | CMC | Global | ||||
| YH009 | RSV | Prevention/ Treatment for RSV infection |
CMC | Global | ||||
| YH010 | PD-L1/IL-12 | Solid Tumors | Discovery | Global | ||||
| YH011 | PD-L1/ cytokine |
Solid Tumors | Discovery | GeneQuantum Healthcare | ||||
| YH012 | Bispecific antibody ADC |
Solid tumors | Discovery | Global | ||||
| YH013 | Bispecific antibody ADC |
Solid tumors | Discovery | Global |
